clinical trial · NCT06255028
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Systemic Lupus ErythematosusLupus NephritisIdiopathic Inflammatory MyopathiesDiffuse Cutaneous Systemic SclerosisCNTY-101IL-2Lymphodepleting Chemotherapy
brief summary
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
started
Feb 6, 2025
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Jan 8, 2026
official title
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol